AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer, in a deal potentially worth more thean $1.5 billion. This is the second major deal this week for Pfizer ...

AstraZeneca will be responsible for optimizing and developing any lead compounds discovered by Broad. In the past 30 years, just two new classes of antibiotics have emerged, despite an alarming ...

Long-term antibiotics use carries the risk of resistance and side effects, representing a gap in the market for a different ...

“We should think before giving antibiotics.” This study was funded by the National Heart, Lung, and Blood Institute. Beigelman reported consultancy with AstraZeneca and Rafa, receiving speaker ...

AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular weight ...

AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

AstraZeneca Plc agreed to buy Icosavax Inc. for as much as $1.1 billion to gain a developer of innovative vaccines for respiratory viruses. Astra offered $15 in cash for each of Icosavax’s ...